Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEASH
2023-504914-31-00Phase 4Completed
- Sponsor
- Krka
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 4, randomised trial of rosuvastatin and sotrovimab in hyperlipidemia and hypercholesterolemia (2 arms), sponsored by Krka. Primary endpoint: Primary: Proportion of patients achieving LDL-C treatment goal at 12 weeks in each arm. Started Nov 2024; status: completed.
02
Drugs
rosuvastatinsotrovimab
03
Conditions
hyperlipidemiahypercholesterolemia
Beyond the preview
Go deeper on 2023-504914-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504914-31-00.